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Abstract
Rheumatoid arthritis (RA) is a chronic, inflammatory joint disease that can lead
to irreversible disability. It affects women in a higher proportion than men (3:1
cases). Several reports suggest a link between female sexual hormones (estrogens)
and RA features. It’s been described that biological processes where basal estrogen
levels are altered like in menstruation, pregnancy, and menopause modifies RA
onset, flare, disease severity, and inflammation. Estrogens have a direct action upon
the immune system though ERα and ERβ receptors, which have distinct affinity to
estrogen concentrations and modifications and have effects upon RA in a dose and
receptor dependent manner. The studies focused on dose dependent response at
experimental settings reveal a wide (from 25 pg/L to several μg/L) and even con-
tradictory spectrum of effects in patients and cells. This chapter summarizes the
contributions and effects of estrogens in RA physiopathology, clinical features, and
discusses the possible contributions of estrogen administration and concentration of
hormone replacement therapy (HRT) to improve the quality of life and reduce the
symptoms of RA patients based on the knowledge of the biology of these hormones.
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1. The RA-gender-hormones link
Rheumatoid arthritis (RA) is defined as a chronic, inflammatory joint disease
that without effective and timely treatment can lead to irreversible disability by
cumulative joint damage. This autoimmune disease is characterized in most cases by
autoantibodies against immunoglobulin G (RF) and citrullinated proteins (ACPAs)
[1–3]. The alterations in the immune response is only one face of the disease since it
has been described as a heterogeneous disease [4, 5]. This is supported by the wide
variation in responsiveness to different rheumatic treatments [6]. Research suggests
this might be due to variations in the distribution/expression of estrogen receptors
(ERs) in immune cells; ERs often bind to promoter regions in the DNA associated
with transcription factors (e.g., NF-κB, SP1, AP-1, C/EBPb) that are important for
immune cell function [7].
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The relation of immune response and estrogens in RA began with the observa-
tion of S. Hench in 1938, where he found pregnancy ameliorated RA, this was the
basis for the formulation of his hypothesis sustaining that hormone deficiency could
lead to the development of RA, but at that moment, he hypothesized adrenal
insufficiency as the responsible of RA pathogenesis [8]. Furthermore, administra-
tion of corticosteroids was prescribed for RA patients and the results of the therapy
were considered “a miracle cure for RA,” but in the case of women, the regulation
of adrenal glands seems to be only a part of the therapy. Other studies demonstrate
that sexual hormones seem to have a very important role in RA pathogenesis. For
example, in vitro studies demonstrated that the achieved concentrations of cortisol
do not affect inflammatory cell function, as did the serum of pregnant women,
which is rich in sexual hormones. Also the corticosteroid levels return to normality
3 days after delivery, which does not coincide with the pattern of rheumatoid
arthritis relapse, common after the third month of delivery [9]. This antecedent
opened a new field of study focused on hormones and RA. When concentrations of
hormones were analyzed in synovial fluid, a correlation was found in this tissue
including, dehydroepiandrosterone (DHEA) which levels are inversely correlated
with disease severity and associated with autoimmunity [10, 11] and
corticotrophin-releasing hormone (CRH) which levels remain constant in synovial
fluids and tissues from RA patients despite the steroid treatment [12]. The
dysregulated production of estrogen levels in RA is not exclusive of women; higher
estradiol (E2) concentrations and decreased androgen levels have been found in
women and men synovia [13]. These concentrations are correlated with those
measured in serum in 66% of the patients (14 of 21 patients). The estradiol mean
concentrations was 38.25–9.74 pg/ml in serum and 18.83–5.70 pg/ml in synovia;
these concentrations showed a positive correlation (R = 0.79, P < 0.0003) [13–15].
Fluctuations in estrogen levels appear to remarkably impact immunologic pro-
file. Estrogen concentration during lactation is slightly low compared to normal
levels (35.9–54.4 pg/ml vs. 63.3–216 pg/ml) upon the normal higher levels (100–
400 pg/ml in the late follicular stage) (Table 1); together, prolactin and estrogen
levels could lead to a change in immune response [16, 17].
2. Prevalence, incidence, and severity of RA in women
Autoimmune diseases affect approximately 8% of the population, out of this
percentage 78% are women [18, 19] and for the specific case of RA, the proportion
Phase Sub phase Estrogen concentration [E2] pg/ml
Ovulation Early follicular 30–100 pg/ml
Late follicular 100–400 pg/ml
Luteal Phase 60–150 pg/ml
Pregnancy 1 semester 188–2497 pg/ml
2 semester 1278–7197 pg/ml
3 Semester 6137–3460 pg/ml
Postpartum Lactation 35.9–54.4 pg/ml
No lactation 97.10 pg/ml
Weaning 81.6 pg/ml
Table 1.
Average levels of estrogens on distinct phases of the reproductive cycle.
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is 3 to 1 compared to men [20, 21]. Also, RA is much more severe in women
compared to men (Table 2). For example, in a multiple logistic regression analysis
for all point and period remissions, male gender seemed to be a strong predictor of
remission; for women, the frequency of remission at 18, 24, and 60 months was
Reference Year Features men Features women Main findings
BARFOT
[22]
2007 DAS28 = 5.09
CRP 27
DAS28 5.37
CRP 18
Women had a much lower remission rate
than men, although their disease activity
before treatment seemed similar
AIR
[23]
2014 DAS28 = 5.6
CRP 32
ERS 34
CCP positives
80.7%
DAS28 5.6
CRP 28
ERS 33
CCP positives
74.7%
At 12 months, men achieved remission more
frequently (18% vs. 12%, P = 0.045). In anti-
TNF failure, remission rates were higher in
men than in women
QUEST RA
n = 6400
[28]
2009 DAS28 = 3.8
ESR 23
HAQ = 0.8
DAS28 4.3
ESR 30
HAQ = 1.1
30% of men and 17% of women in QUEST-
RA were in DAS28 remission
AIR
n = 1709
[23]
2014 Lower frequency
of anti-CCP
(P = 0.03)
Lower CRP (P
< 0.001)
Female had longer disease duration
At 12 months, men achieved remission more
frequently (18% vs. 12%, P = 0.045)
Table 2.
Baseline and remission characteristics of RA in men vs. women: comparison of different clinical characteristics
of female RA patients compared to male RA patients and the difference in remission rates documented on
various studies.
Figure 1.
E2 cell receptors in different cell populations: different effects of estrogen concentrations upon estrogen receptors
ER-α and ER-β present on each cell. Left: receptors and cells were they are present. Horizontal red arrow:
gradient of estrogen concentrations. Blue arrows: decrease of an effect by estrogen concentration. Red arrows:
increase of an effect by estrogen concentrations. This is an original image made explicitly for this publication
and not subject to copyright.
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30.4, 32.1, and 30.8%, respectively; meanwhile for men, the remission rate was
41.7, 48.0, and 52.4% [22]. Additionally, in another study from a total of 1709 RA
patients, (77% female) women had a longer disease duration (P < 0.001) despite
the fact that at baseline, women had a lower frequency of anti-CCP positivity
(P = 0.03) and lower CRP (P < 0.001), and at 12 months, men achieved remission
more frequently (18% vs. 12%, P = 0.045) compared to women [23].
The estrogen dysregulation has been associated with disease severity and accel-
eration of lumbar facet joint damage in arthritis [24, 25]. Added to this, some
disorders of the reproductive system seem to increase the risk to develop RA, for
example, physician-diagnosed polycystic ovary syndrome (RR 2.58; 95% CI, 1.06–
6.30) and endometriosis (RR 1.72; 95% CI, 0.93–3.18) [26]. [27]. Suggesting an
important role of sex hormones and menstrual cycle regulation as risk factors
associated with autoimmune diseases.
These differences could be attributed to the fact that women respond after
immunization with a more exacerbated antibody production and an increase in cell-
mediated responses. Thus, female patients show higher CD4+ T-cell counts, higher
levels of IgM, and T-helper 1 (Th1) cytokine production [29]. This suggests that
differences in immune response could be mediated by the hormonal ratios observed
during pregnancy and postpartum in women with RA.
There is an increased risk of RA worsening or new onset of disease especially
after the first trimester postpartum (Table 3), where several immune and hormonal
changes are detected like: elevation of monocyte-related transcripts [30], decrease
in corticosteroids, estrogen, progesterone, IL-4, IL-10, and humoral immunity, and
increase of TNF-α and IFN-γ [31]. These postpartum flares occur within the first
4 months in most patients with chronic RA [32, 33], even a 62% had more affected
joints at postpartum; these results were similar when the analysis was restricted to
tender joints only [32]. Aggravation of disease activity (in 6 of 9 patients with RA)
was detected at 6 and 12 weeks postpartum as a progressive decrease in leucocyte
counts and increased CPR, whose levels where normal during pregnancy [34]. In
Figure 2.
Estrogen modifications and concentrations: image showing the differences between the effects depending of the
estrogen modifications. Activity of different estrogen modifications upon proliferation of THP-1 cells and
concentrations needed for achieve the effect. Green lines: increase in proliferation. Red lines: decrease in
proliferation. This is an original image made explicitly for this publication and not subject to copyright.
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the “Pregnancy induced Amelioration of Rheumatoid Arthritis” (PARA) study, 118
patients were followed up until 26 weeks postpartum and levels of autoantibodies
anti-CCP, IgM-RF, IgG-RF, and IgA-RF were measured. The median levels of
autoantibodies during pregnancy were stable and declined postpartum. When
hemodilution was taken into account, an increase in the levels of antibodies explains
the symptom onset as well as the start of symptoms due to inflammatory processes
directly related to immunoglobulin actions [8].
These dramatic postpartum changes can explain why there is a three to fivefold
increased risk of onset during the first 3 months postpartum, with the highest risk
being after a first pregnancy [35], in the cohort of Iijima composed by 2547 patients,
and the same results were obtained [33]. The available studies on pregnancies in
women with RA suggest that outcomes are worse than in the general population [36].
Such RA onset coincides with hormonal changes in the postpartum period, and
only the changes during postpartum contribute to RA. During breastfeeding pro-
lactin [40] by itself increases the antibody production and pro-inflammatory cyto-
kines [41] and after the first pregnancy the risk of RA increases several times [42].
An additional link between sex-hormones and increased risk of RA come from data
showing that the administration of drugs for lactation suppression which mainly are
high-dose estrogens, increased risk of RA development [26]. Given that several
cytokines are regulated by estrogens, so a decrease in this hormone could be
responsible for flare and disease onset as it contributes to the activation of the
immune system necessary for the delivery [43].
Estrogen seems to orchestrate several key features of the immune response and
may be a critical factor in the incidence and severity of the disease in women. Small
variations in estrogen concentration can have a very wide range of effects, even
some of them could be opposite even when they are provoked by the same molecule.
3. Influence of reproductive cycle hormones and their role in RA
immune response
3.1 Arthritis and menstruation
Since 1980, it was noted that young women with rheumatoid arthritis (RA)
report an exacerbation of symptoms just before or at the time of menstruation, it
could possibly be related to “premenstrual tension syndrome” and alteration in pain
perception [44], but in a study where only objective measures of disease activity
Reference Period evaluated after delivery
(months)
Percentage/fold increase of RA
onset
Oka [37] <6 9.7%
2.7%
6–12
Del Junco et al. [38] N.E. 5 fold
Nelson et al. [39] <6 9.7%
Iijima et al. [33] 12 0.08%
Silman et al. [35] 3 5 fold onset
Ostensen et al. [34] 3–6 66.6%
Table 3.
Percentage of healthy subjects who presented RA onset after delivery or post-partum.
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were measured, a significant cyclical change in finger joint size (FJS) was seen in
4 of 7 patients with RA, with all peaks occurring within 6 days of the start of
menstruation [45] while on contrary, the morning stiffness was reduced during the
post-ovulatory phase where estrogen and progesterone are high [46], indicating
that this worsening of symptoms might be related to variations in hormone levels
[47]. Based on this evidence, a relation between low levels of estrogen (at luteal
phase) can correspond to enhancement of RA symptoms. Contrary to what occurs
on pregnancy, where high estrogen levels seem to have a protective effect. Until
now there is no follow up study available to display the effect of cyclical variations
in estrogen levels and symptoms severity in RA patients.
3.2 Arthritis and pregnancy
As stated previously, the relationship of RA onset and sex hormones has been
widely studied. This phenomena was described first 80 years ago [8] and was
noticed that pregnant patients with RA usually go into remission [48] in a 20–40%
by the third trimester and 50% had low disease activity [49]. Prospective studies
have shown that only 48–66% of women with RA experience improvement in
pregnancy, with 20% becoming quiescent by the third trimester and 16% in com-
plete remission (no joints with active disease without therapy) [32, 50].
It has been hypothesized that estradiol might be the principal regulator of
immune response during pregnancy, nevertheless other estrogens might be impli-
cated in this immune regulation, as an example we can cite estriol (E3) which is
mainly produced during pregnancy [51, 52], and estetrol (E4) is synthesized exclu-
sively by the fetal liver during pregnancy being able to reach the maternal circula-
tion through the placenta [53]; thus, these two estrogens, specifically E4 could have
an important role in the immune regulation during pregnancy; nevertheless, there is
scarce information about its possible function during pregnancy.
A shift from a Th1/Th17 pro-inflammatory response to a Th2/Treg response has
been observed in pregnancy [54, 55]. This could explain the decrease of IL-2 during
pregnancy, while soluble TNF receptor, p55 and p75, increases [56]. The role of the
immune system in pregnancy is very important. It has been observed that a deple-
tion of immune cells can cause the termination of the pregnancy. Nevertheless, it is
not very clear how such changes in T helper cell function could impact the implan-
tation process. It has been suggested that the response could be induced by tropho-
blastic cells that can secrete IL-6, IL-8, MCP-1, and GRO-α, early in pregnancy [43].
During the first trimester, NK cells, dendritic cells, macrophages, and regulatory
T cells (Treg) infiltrate the decidua and accumulate around the trophoblastic cells
[57–59]. This regulation of the immune response could be the cause beneath the
clinical improvement observed in RA during pregnancy.
3.3 Menopause and arthritis
RA onset is common in the peri-menopausal age, which is not the case with SLE
[60] and while hormone replace therapy (HRT) is proposed as therapy for women
with RA, OCP and postmenopausal hormones significantly increased the risk of SLE
[61]. Also, there is an inverse trend for RA incidence when women reach meno-
pause after 51 years compared to those who reach menopause before 45 years of age.
This is consistent with a decline in the production of sex hormones and suggesting
that changes in immune regulation due to the availability of estrogen receptors in
immune cells and circulating estrogens might also have an effect on RA onset on
these late menopausal women [26].
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4. Molecular aspects of estrogen effects in immune response
4.1 Regulation by estrogen receptors
ERα (NR3A1) and ERβ (NR3A2) that are encoded by ESR-1 and ESR-2 genes
expressed on human chromosomes 6 and 14, respectively [62]. It is estimated
that both receptors regulate 40% of the genes in cell line U2OS [63], but despite
both are estrogen receptors (ERs), ERα and ERβ microarray analysis had demon-
strated that they regulate different genes [7, 64, 65]. The activation of one or other
of these ERs has specific effects in distinct, non-overlapping or even antagonist
effects determined by factors like distribution, expression, dimerization, splice
variant ER isoforms, signaling pathways triggered, physiological stage, and interac-
tion with specific co-activators/repressors [62]. One example of the distribution
of these receptors is given in T lymphocytes, CD4+ cells which have higher ERα
levels, B cells have higher ERβ expression than ERα and CD8+ cells have lower
expression of both receptors [66], murine splenic DCs express ERα but has negligi-
ble ERβ expression and bone marrow-derived and peritoneal macrophages also
express ERα and few if any ERβ [67, 68], so given the expression, lower or higher
concentrations of estrogens will be needed to activate the receptors with the lowest
expression [69].
In general terms, the effect of ERα on the immune system is more prominent
than ERβ due to regulating multiple NF-kB pathway members to control cytokine
responses. This, given that ERs are ligand-dependent transcription factors that
mediate long-range chromatin interactions and form complexes at gene regulatory
elements, thus promoting epigenetic changes and transcription [70]. Also, its pro-
motion of strong antigen-specific Th1 cell responses was demonstrated in ERα-
deficient mice where E2 effects on Th1 responses were not observed [71], apart
from but this receptor is not only delimited to the cells at periphery, its expression
seems to have effects in the thymus and spleen since deletion of ERα led to
hypoplasia of both organs and contribute to the increased frequency of immature
CD4 + CD8+ thymocytes and decreased CD4 + CD8 cells [72].
4.2 Estrogen dose and receptor dependent effects
As mentioned previously, estrogen receptors (ER) are expressed in the immune
cells; TaqMan RT-PCR analyses indicate that in CD4 + T-helper cells express higher
concentrations of ERα, B cells ERβ, and CD8+ T cells; monocytes express both ERs
at lower concentrations [66]; this proportion is important because despite both
receptors are present in all PBMCs, the functions elicited by their activation vary
depending on the proportion of each receptor on such cells. A wider description of
such differential effects is made for several cell types:
T cells: CD4+ T responds to E2 administration at low physiological levels (of
60–100 pg/ml in castrated female mice) increasing antigen specific responses,
production of IFNγ and IL2 as well as inducing FoxP3 positive Treg cell differenti-
ation [71, 73–75]. During the reproductive cycle CD4+, T cells increase on preovu-
latory (late follicular) [76], decrease in the luteal phase (60–150 pg/ml) compared
to the early follicular phase (30–100 pg/mL) [77] and increased in the first trimester
of pregnancy (8.9%, vs. 4.4% of controls) and 6–8 weeks following delivery [78].
Regarding CD8+ T cells, there is not much evidence, in models of collagen-II induce
RA, CD8+, lymphocytes were significantly diminished in the spleen of the estradiol-
treated animals and were suppressed in the thymus [79].
Fibroblast-like synoviocytes: on FLS, estrogens induce an increase of MMP
invasion of cartilage when these cells were transfected with ERα, thus estrogen
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levels can influence joint erosion degradation of extracellular matrix [80]. Regard-
ing this antecedent, an increase in hormonal levels at synovia could influence
cytokine levels but it is not clear if the effects of estrogen upon certain cytokines
like TNF-α, IL-10, and IL-6 are unidirectional or could be an initial trigger of
aromatase activity. For example, TNF-α, IL-1, and IL-6 stimulate fibroblast aroma-
tase activity in a dose-dependent manner; the aromatase enzyme complex is
involved in the peripheral conversion of androgens (testosterone and androstene-
dione) to estrogens (estrone and estradiol, respectively) [81].
B cells: concentrations of E2 ranging 75 pg/ml or above activate ERs, leading to
an upregulation of CD22, SHP-1, BCL-2, and V-CAM-1. This can alter the survival
of immature B cells that would normally be deleted [82]. Also a decrease in transi-
tional B cells and increased marginal zone B cells [83] has been observed. In the
presence of estrogen, BAFF increased its expression by 5-fold, but this characteristic
was more pronounced in cells isolated from women than in those from man [84].
An overexpression of BAFF in transgenic mice leads to manifestations of autoim-
mune disease [85], and similar BAFF increase has been reported in the serum of
patients with RA, [86] even at early stages of RA and correlates with the titers of
IgM rheumatoid factor and anti-cyclic citrullinated peptide autoantibody (R = 0.76
and R = 0.49) [87]. It has been hypothesized that high levels of estrogens during
pregnancy could prevent B cell apoptosis and therefore enhance survival of
autoreactive cells [88]. Implications of estrogen signaling on auto reactive B cell
expansion and autoantibodies production have not been evaluated in the clinical
setting.
Another field with scarce exploration and understudied outcome of the estrogen
therapy on RA is the modification and decrease of autoantibodies by estrogen
action. This novel mechanism is not clearly elucidated and a lot of investigation in
this topic is needed, but the little existing evidence demonstrate that estrogens can
influence antibodies production and activity by modification of glycosylation of
antibodies like galactosylation of human IgG in healthy individuals [89]. The
changes in immunogenesis of antibodies by estrogens was demonstrated in an
experiment were the induction of anti-C11 autoantibodies was measured, lower
anti-C11 levels were observed in the estrogen treated group as compared with their
controls [90]. The same behavior was observed by Nielsen et al. [91] and further
investigations demonstrated than on CIA models sustained levels of 0.36 mg of
estradiol (comparable to estrus phase) had similar quantities of IgG anti-CII anti-
bodies than controls but have not developed RA, this was due to the different Ig
subclasses. Estradiol-treated mice produced more IgG1, and mice from the placebo
group produced significantly higher levels of IgG3 [92]. Other changes that estro-
gens induce in autoantibodies are an increase in sialylation, which has been
observed during pregnancy and within 3 months post-delivery (when RA risk is
presumably higher) [93]. Antibodies sialylation affects inflammation; in the case of
RA, the transition from preclinical asymptomatic autoimmunity to clinical phases is
associated with a change in the sialylation of antibodies [94–96]. Changes in
sialylation by estrogens have been explored already in RA patients. E2 treatment
increases sialylation on postmenopausal RA women [97], so taken together if E2
induces anti-inflammatory IgG by inducing St6Gal1 expression in antibody-
producing cells [98].
4.3 Estrogen effects: dependency on concentration and chemical modifications
Estrogen concentration: it seems to exist a cut-off point in the concentration of
estrogens that determine different effects, because sensitivity of receptors even at
sub physiological concentrations of estrogens. For example, in a model of collagen-
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induced arthritis (CIA) in female mice, after type II collagen (CII) immunization
those treated with the ER antagonist ICI 182,780 (which binds to both ERα and ERβ
but not to the surface receptor) doses that insufficient to block estrus cycle, were
sufficient for block the E3-mediated suppression of CIA [99, 100]. On the range of
higher concentrations, estradiol (E2) can inhibit the production of pro-
inflammatory cytokines, like TNF-α, (IL)-1 β, and IL-6 and induce anti-
inflammatory cytokines such as IL-4, IL-10, and TGF-β (Th2 phenotype). On the
contrary, low concentration of E2 stimulates TNF, INF-γ, and IL-1 β production and
exerts an inhibitor effect on NK cells [101, 102]. In brain tissue, it was demonstrated
that 2-OH-estradiol protects neurons from oxidative stress at nanomolar concen-
trations (10 nmol/L) but 17-β-estradiol showed oxidative effects only at micromolar
concentrations (1–10 μmoI/L); these concentrations were in the order of magnitude
expected to activate their receptors (10–1000 nmol/L) demonstrating that physio-
logical levels of estradiol may protect through receptor-dependent mechanisms
from mitochondrial ROS, whereas higher concentrations may act through indepen-
dent ER mechanisms [103]. This wide range of dose dependent effects could sug-
gest us that a difference exists in the actions of estrogens between reproductive
organs and its effects in the immune system. With respect to pro inflammatory
cytokines such as TNF-αβ IL-1 and IL-6, estrogen effects seem to be bimodal where
pharmacological concentrations (Table 3) of 50,000–100,000 pg/ml (equivalent to
100 μg/L or 106 M) decrease or inhibit the cytokine production and physiological
concentrations of 5000 pg/ml increase cytokine production [104, 105]; this agree
with other results where macrophages treated with doses of 0.001–100 nM
(109 M) equivalent to therapeutic concentrations of estradiol for 24 reduced LPS-
induced TNF-α production [106]. Despite all evidence there is no clear explanation
about how estrogens (estradiol or estriol) interfere in the clinical outcomes and
immune response in RA depending on ERα/ERβ or evidence of the effects associ-
ated to a certain dose range. This could be useful for the development of more
selective ERα or ERβ agonists and antagonists.
Estrogen chemical modifications: as mentioned before, a correlation exists
between estrogen concentration in synovial fluid and serum estrogens (R = 0.79, P
< 0.0003), and concentration of free estrogens (E2) is higher in RA as compared to
controls [13–15]. Therefore, measured estrogen concentration in synovia could
reflect a general overview of estrogen body concentrations. There is a significantly
higher level of androstenedione (a precursor of estrone and estradiol) in synovial
fluid of RA patients as estrone (E1), suggesting that these higher levels are the result
of an elevated activity of aromatase [14]. Available steroid pre-hormones are rapidly
converted to estrogens, which seems to have pro-inflammatory activity in the
synovial tissue. When analyzed more in detail, it was found that increased estrogen
concentrations in RA synovial fluid (in women as in men) were 16α-hydroxyestrone
and 4-hydroxyestradiol (hydroxylated forms), while the estrone levels were
detected increased on RA patients, the 2-hydroxyestrone showed no differences
comparing RA vs. healthy controls [14], and depending on its modifications, estro-
gens can trigger very different effect in the body. For example, the hydroxylated
forms of estradiol, 16OH-E2 and 2OH-E2 enhance the proliferation of THP-1
monocytes at high concentrations (109 M). Meanwhile, the hydroxylated estrones
4OH-E1 and 2OH-E1 enhance cell proliferation at low concentration (1010 M),
[107], which are inhibited by antiestrogen drugs [108], except for 2OH-E1, which
still induced proliferative effect (10–10 M) [107]. In some cases, estrogens produce
the same affect but have different target cells in a dose dependent manner because
of the proportion of expression of ERs; E2 and endocrine disrupting chemicals
(EDCs) affect cell mutagenesis through ERα. At 10–8 M is observed an inhibition on
the mitogenesis of B cells and at 10–6 M in T cells. For the EDCs (diethylstilbestrol,
9
The Role of Estrogens in Rheumatoid Arthritis Physiopathology
DOI: http://dx.doi.org/10.5772/intechopen.93371
bisphenol-A, p-nonylphenol, and di-2-ethylhexylphthalate), the concentrations
needed for this effect were higher, from 10 to 6 to 10–5 M [69].
5. Estrogens and their possible ameliorative effect upon arthritis:
therapeutic approach
Given the previously displayed effects of estrogens on the immune system and
in RA, it is natural to suppose that a hormone therapy could have certain effects
upon the disease but, the studies exploring this possibility are scarce. Three major
considerations have been identified as roadblock for such research to be conducted:
(1) cut-off point in estrogen levels determining the effects of this molecule on the
immune system, (2) the various effects of the same molecule at different concen-
trations lead to different effects depending ERα or ERβ receptor, and (3) effects
dependent of the chemical modification (hydroxylation) of estrogens.
The hypothesis that hormonal therapy could ameliorate RA arises from the
evidence of reported improvement in multiple pregnancies and contraceptive use
[109], but this evidence became more solid when the estrogen at physiological
levels administration in models of type II collagen-induced arthritis model (CIA)
ameliorated arthritis and suppressed T-cell-dependent autoimmune reactions
[52, 90]. In this experiment, female mice were implanted with E2 release devices,
which induced a chronic estrous phase, the high doses of E2 caused a 35-day delay
of the onset of RA disease but without affecting frequency and severity; this delay
was reduced to 10 days with lower E2 concentrations of 25 days with physiological
E3 proved to be as efficient as the high dose E2 causing a 25 day delay [90]. E3
seems to have more pronounced effects than E2; this estrogen E3 is mainly pro-
duced in pregnancy [51, 52]. In EAE models, it seems that the estrogen-mediated
protection is dependent upon ERα. For example in EAE homozygous ERαKO
treated with estriol, no protective effect was registered, while WT mice presented a
significant decrease in disease severity and significant reductions in pro inflamma-
tory cytokines TNF, IFNγ, IL-2, and an increase in levels of the Th2 cytokine IL-5
[110]. The effect of estrogens at interact with ERα receptor is not only limited to the
immune response; in murine ovariectomized mice with estrogen treatment by
pellet implantation, a dramatic increase in bone mass was observed. This was
mediated by ERα-mediated apoptosis of osteoclasts through activating FasL/Fas
signaling [111]. This could be an indicator that similar protective effects of estro-
gens may be present in immune cells due to the expression of ERα in CD4 + T
lymphocytes.
Estrogens have been demonstrated to have anti-inflammatory activity. In CIA
models, estrogen supplementation reduced paw inflammation efficiently and
decreased paw volume by 48% (P < 001) [91], but we need to be aware that the
activity of several estrogens (E1, E2, E3, and E4) is different and it depends not only
on the hormone itself but also by the specific disease or even the specific clinical
profile of the patient that is taking them. 2-methoxyestradiol on CIA model
(20 days after the injection of type II collagen) produce a significant decrease in the
arthritis index compared with that in the control mice (P < 0.05) despite it was not
as efficient as estradiol [112]. Despite this is the most tested estrogen among studies
for its effect in RA, Estradiol E2, in clinical applications, shows several side effects
such as: hypertension, increased coagulation, and cancer incidence but a feature
that both share is that they are protective in experimental autoimmune encephalo-
myelitis (EAE) and CIA [113].
The clinical data available is scarce and most of the available trials only evaluate
the protective effect of OCP (oral contraceptive pill) and hormone replacement
10
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therapy (HRP) for RA. In a study of association between postmenopausal hormone
therapy (PMH) use and the risk of rheumatoid arthritis (RA) in a subset of the
Epidemiological Investigation of RA (EIRA) study, the users of PMH had a
decreased risk of ACPA-positive RA compared with never users, mainly with a
combined therapy (estrogen plus progestagens), they propose that PMH use might
reduce the risk of ACPA-positive RA in post-menopausal women over 50 years of
age, but not of ACPA-negative RA [114].
Regarding the role of OCP use in RA, there is a theory which explains that recent
decrease in incidence of RA in women in the past 50 years may be in part due to
increased use of the OCP, even when may be confounded by OC use being related
to pregnancy avoidance and high social class [115]. During a 14 month period,
23,000 women who were using oral contraceptives were recruited, and a similar
number of those who had never used OCP as controls and evaluated every 6 month
intervals. Patients were classified as “current user,” “former user,” and “never
user.” The cases were categorized according to the woman’s contraceptive status at
the time of RA diagnosis (event). The trend for former users was χ2 = 5.7, (p
< 0.02) and for the never users χ2 = l5.0, (p < 0.01) but the current users χ2 = 0–85,
(p > 005) and for those who were aged 40–44 years at diagnosis had a significantly
lower risk of rheumatoid arthritis than similarly aged never users (relative risk
0.29). At the end of the follow-up, women who were using the pill at the time of
diagnosis had a statistically non-significant 20% reduction in their risk of rheuma-
toid arthritis but early in the study current users had a significant 50% risk reduc-
tion [116]. The same cohort was classified in groups of “takers” and “never takers”
and was analyzed too for the incidence of RA. The standardized rate for takers was
49% of the control rate (p < 0.01) and resulted interesting an observed tendency
for an increased incidence of RA forward 35 years; this tendency was conserved
only in the group of “never takers” and suppressed in the takers [117].
wIn the Swedish EIRA study (population-based case-control) including 2641 cases
and 4251 controls participants were questioned about OCP (oral contraceptive pill) full
term need to be mentioned consumption, and potential confounders in order to calcu-
late the ORs adjusted for age, residential area, smoking, and alcohol consumption.
Compared with never users, the OCP users had a decreased risk of ACPA-positive RA
(OR = 0.84) (95% CI 0.74–0.96) compared to the never users. Also the consumption
for more than 7 years decreased the risk of both ACPA-positive (p = 0.0037) and
ACPA-negative RA (p = 0.0356) compared to never users of OCP [118].
Most of the studies agree that the current or ever use of the OCP has a protective
effect against RA, probably more delaying the onset rather than a preventing RA.
But until now there is not a final conclusion because even the meta-analysis results
are contradictory. In the meta-analysis of six case-control and three longitudinal
studies, the overall pooled odds ratio of the studies was 0.73 for the adjusted results
(95% CI 0.61–0.85) with the conclusion that OCP consumption prevents the pro-
gression to severe disease by modifying the disease process [119]. On the contrary in
a meta-analysis performed by Qi et al. in 2014, the authors identified 1116 publica-
tions in PubMed and EMBASE databases. The meta-analysis of 12 case-control and 5
cohort studies were analyzed. Potential publication bias was evaluated using Begg’s
funnel plots and quantified by the Egger’s test, as a sensitivity analysis was
performed to investigate the influence of potential confounding factors like age,
smoking, parity/pregnancy, body mass index, and social class on risk of develop RA.
Here, no statistically significant association was observed between oral contracep-
tives and RA risk (RR = 0.88, 95% CI = 0.75–1.03) concluding that OCP consump-
tion was not significantly associated with RA risk [120].
HRT (hormone replacement therapy) has been studied in regard to RA new-
onset. On a study in a prospective cohort of 31,336 Iowa women (from 55 to
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69 years) followed up during 11 years, 158 incident cases of RA were registered. Of
the factors that showed an inverse association with RA, the authors identified preg-
nancy (P trend =0.01) and age at menopause (P trend =0.03), whereas polycystic
ovary syndrome (relative risk [RR], 2.58; 95% confidence interval [CI], 1.06–6.30),
endometriosis (RR, 1.72; 95% CI, 0.93–3.18), and hormone replacement therapy (RR,
1.47; 95% CI, 1.04–2.06) were positively associated with RA. If HRT is administered
before RA is associated with a higher risk of developing the disease, studies suggest
that when HRT is administered during RA, they have a favorable effect. In 88
postmenopausal women with RA who received HRT, vitamin D3, and calcium sup-
plementation or vitamin D3 and calcium supplementation alone for 2 years, HRT use
had a significant effect upon active RA, ameliorating effects on inflammation (ESR
p = 0.025) DAS28 (p = 0.036) and was associated with slower progression of radio-
logical joint destruction (p = 0.026) [121]. The continuous hormonal therapy given to
suppress menstruation for regulation of menstrual bleeding, pelvic pain, and
dysmenorrhea seems to have demonstrated improvement in RA [122].
6. Novel hormone analogs in RA
Recently, novel hormone analogs have been developed. ERB-041 is a selective ERβ
agonist and has showed interesting effects in several inflammatory rodent models,
including endometriosis, rheumatoid arthritis, inflammatory bowel, and sepsis
[123, 124] where a strong effect on reduction of inflammation was observed. This
selective effect was the antecedent for the development of other ERβ agonists like
MF101 [125] that could be useful to modulate the inflammation and cytokine pro-
duction in RA. No clinical trial data on these molecules have been published so far.
7. Conclusions
Given the higher prevalence of RA cases that occur in women, is natural to suspect
that such differences are due to sexual hormones, specifically estrogens, which have
been explored as part of pathophysiology, development, and progression of RA
disease. Antecedents point to estrogens as strongmodulators of immune response and
function associated to RA. The role that sex hormones play in the development, cell
activation, and alterations in immune function in autoimmune diseases is still a
matter of intense research. The administration of estrogens may have a protective
effect on RA development or in the onset of disease, delaying it. Also, experimental
evidence suggests that estrogens demonstrated anti-inflammatory activity in animal
models of RA. Such effects are mediated bymodifications in antibody production and
in post-translational modification of antibodies like sialylation (addition of syalic
acid), involved on increased risk of RA in conditions with low estrogen levels such as
menopause. Estrogens administration to RA patients could be a strategy to improve
the quality of life through hormone replacement therapy (HRT). This, in resource
limited settings were biological therapy cannot be afforded and in patients that are
refractory to standard MTX therapy or that have failed to respond to such therapies.
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